CureVac

COVID-19 accelerated mRNA vaccine development, leading to record profits and FDA approval of mRNA vaccines. Moderna and Pfizer/BioNTech are expanding their mRNA pipelines into other diseases, with Moderna's RSV vaccine recently approved. The mRNA therapeutics market is projected to reach $68 billion by 2030. mRNA technology is favored for its rapid development potential compared to traditional vaccines. Five mRNA vaccine candidates, including Pfizer/BioNTech's influenza vaccine and Moderna's combination COVID-19/influenza vaccine, are highlighted as near-future prospects.

Early switch to atezolizumab after vemurafenib plus cobimetinib in BRAF V600-positive melanoma showed improved OS at 4 and 5 years in the ImmunoCobiVem trial, but not statistically significant. Rapid progression after switch to immune checkpoint inhibition was observed in some patients.

GSK's phase II trial for mRNA seasonal flu vaccine met success criteria in both younger and older adults, showing acceptable safety and reactogenicity. The mRNA platform elicited strong antibody responses, prompting progression to late-stage development. GSK aims to create a best-in-class vaccine for greater flu protection.

GSK reports positive interim Phase II trial results for its mRNA-based multivalent influenza vaccine candidate, GSK4382276A, meeting pre-defined success criteria in both younger and older adult groups. The vaccine, encoding antigens matched to WHO-recommended influenza strains, showed potential for improved immune responses compared to current vaccines, prompting GSK to advance the programme into late-stage clinical development.

GSK's mRNA-based seasonal flu vaccine successfully completed phase II trials, showing positive immune responses and safety profiles, advancing to phase III. The company's full control over development and manufacturing from CureVac, along with AI/ML-based optimizations, strengthens its mRNA vaccine program. GSK's financial stability, with a market cap of $88.32B and a dividend yield of 3.46%, supports ongoing vaccine technology investments.

CureVac N.V.’s press release includes forward-looking statements about future events and results, such as potential vaccine efficacy, strategies, financing plans, and market growth. These statements are not guarantees and are subject to risks, including economic conditions, regulatory approval, competition, and the COVID-19 pandemic. The company does not update forward-looking statements and advises readers to consult SEC filings for further information.

GSK announces positive phase II data for mRNA seasonal flu vaccine, showing strong immune responses and safety profile, supporting progression to phase III trials.